Apples to Apples: Playing the Comparability Game in Biotherapeutics Development

Comparability studies are a significant issue for those working in biotherapeutics development, as undetected product changes are considered high risk.

Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to get important insights and recommendations on how to successfully plan your clinical and CMC manufacturing development plans to reduce your regulatory risk along the way.

Learning Points

  • The importance of comparability studies for biologics
  • Key aspects of a comparability assessment
  • How to determine analytical and stability parameters when measuring comparability
  • Conditions for evaluating stability studies

LISTEN TO PODCAST

 

Meet Veristat. Learn More.

1 min read

Chief Medical Officer Summit -CMO 360°

Meet the Veristat team at Booth #3, April 17th and 18th in Boston

The Science-First CRO™ and Consultancy Ready to...

4 min read

Plenary Session Presentation: Putting Science First in Rare Disease Studies

Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at...